Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
February 21, 2018 8:42 AM ESTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.
... MoreHalozyme Therapeutics (HALO) PT Raised to $22 at JPMorgan
February 21, 2018 7:24 AM ESTJPMorgan raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $22.00 (from $19.00) while maintaining a Overweight rating.
... MoreHalozyme Therapeutics (HALO) PT Raised to $24 at Deutsche Bank
February 21, 2018 6:55 AM ESTDeutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More
